Mavatar today announced the addition of networks of Alzheimer’s disease, glioma and other neurological disorders to its research platform, Mavatar Discovery, enabling researchers and pharmaceutical scientists to explore neurodegenerative disease biology at a systems level. The new resource will be formally introduced to the scientific at the AD/PD International Conference on Alzheimer's and Parkinson's Diseases taking place in Copenhagen from March 17–21, 2026.
Mavatar Discovery is a data-driven research platform designed to help scientists move from gene lists to biological mechanisms. By integrating thousands of transcriptomic datasets across diseases and tissues, the platform enables users to build gene-to-gene networks and explore how genes interact within biological systems. This allows both academic researchers and pharmaceutical R&D teams to identify disease mechanisms, generate new hypotheses, and support target discovery.
Researchers attending the conference will be able to explore the Alzheimer’s disease networks through live demonstrations of Mavatar Discovery at Booth #57, where the platform will showcase how systems-level biological analysis can reveal relationships across genes, pathways, tissues, and related diseases.
Powered by Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework, the platform integrates large-scale molecular datasets to uncover biological relationships that may not be visible through traditional single-gene analysis. The newly integrated Alzheimer’s disease and general dementia networks allow users to investigate molecular interactions, regulatory pathways, and gene relationships associated with neurodegeneration within a broader biological context.
The launch is taking place in collaboration with leading Alzheimer’s researchers, including Tomas Deierborg, Professor of Experimental Medical Science at Lund University.
“Understanding Alzheimer’s disease requires looking beyond individual genes - and even beyond individual tissues - to the broader biological systems that drive neurodegeneration, integrating insights from both brain and blood,” said Deierborg. “Platforms that integrate diverse molecular datasets and reveal network-level relationships can help researchers generate new hypotheses and better understand the complex mechanisms underlying Alzheimer’s disease.”
Early exploration of the platform has already produced promising insights.
“Initial exploration of Mavatar Discovery has identified biological signals that could be highly relevant to our current Alzheimer’s research identifying new targets,” Deierborg added. “The platform highlighted relationships that were not immediately visible through conventional approaches and that are extremely interesting for our ongoing work. We are now continuing our investigations to better understand these findings.”
The Alzheimer’s disease networks launched this week represent the first step in an expanding initiative. Mavatar plans to continue developing these networks together with input from leading researchers in the Alzheimer’s field.
To mark the launch, Mavatar will host an invite-only VIP dinner during the AD/PD conference, where Deierborg will moderate a panel discussion with prominent Alzheimer’s researchers including:
- Gunnar Gouras, Professor, Lund University
- Mikael Heneka, Professor, University of Luxembourg
- Henrietta Nielsen, Associate Professor, Stockholm University
- Malin Wennerström, Researcher and Group Leader, Lund University
- Danuta Gawel, Chief Research and Development Officer at Mavatar
Insights and feedback from these and other experts will help guide the continued development of Alzheimer’s disease networks within Mavatar Discovery.
“The addition of Alzheimer’s disease network along with other neurological disorders represents an important step in expanding the scope of Mavatar Discovery for neurodegenerative disease research,” said Danuta Gawel, Chief Research and Development Officer at Mavatar.
“By integrating diverse molecular datasets and applying our DINA framework, we aim to provide researchers with tools to explore complex disease biology at a systems level and uncover insights that may support the development of new therapeutic strategies.”
Researchers and industry scientists attending AD/PD are invited to visit Booth #57 to see the Alzheimer’s disease networks in action.